• 1
    Lee WM. Hepatitis B virus infection. N. Engl. J. Med. 1997; 337: 173345.
  • 2
    Dienstag JL, Schiff ER, Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30: 10827.
  • 3
    Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J. Viral. Hepat. 2002; 9: 20812.
  • 4
    Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 8036.
  • 5
    Lee CM, Ong GY, Lu SN et al. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J. Hepatol. 2002; 37: 66974.
  • 6
    Dienstag JL, Cianciara J, Karayalcin S et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37: 74855.
  • 7
    Ryu SH, Chung YH, Choi MH et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J. Hepatol. 2003; 39: 61419.
  • 8
    Kato H, Ruzibakiev R, Yuldasheva N et al. Hepatitis B virus genotypes in Uzbekistan and validity of two different systems for genotyping. J. Med. Virol. 2002; 67: 47783.
  • 9
    Allen MI, Gauthier J, DesLauriers M et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J. Clin. Microbiol. 1999; 37: 333847.
  • 10
    Hsu YS, Chien RN, Yeh CT et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 15227.
  • 11
    Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. 1996; 334: 14227.
  • 12
    Chien RN, Liaw YF, Atkins M, Asian Hepatitis Lamivudine Trial Group. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30: 7704.
  • 13
    Leung NW, Lai CL, Chang TT, Asia Hepatitis Lamivudine Study Group et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 152732.
  • 14
    Nafa S, Ahmed S, Tavan D et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32: 107888.
  • 15
    Tassopoulos NC, Volpes R, Pastore G et al. Lamivudine Precore Mutant Study Group. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 88996.